Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 7/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245832 | 0.95 | CYP11B1 (0.43) | CYP11B1CYP11B2TRPV4MAOBMAOA | |
| SCHEMBL6396748 | 0.94 | CYP11B1 (0.42) | CYP11B1CYP11B2TRPV4MAOBMAOA | |
| SCHEMBL2428048 | 0.92 | CYP11B1 (0.45) | CYP11B1CYP11B2TRPV4MAOBMAOA | |
| SCHEMBL12460721 | 0.85 | CYP11B1 (0.45) | CYP11B1CYP11B2TRPV4MAOBPLA2G7 | |
| SCHEMBL3565152 | 0.85 | CYP11B1 (0.45) | CYP11B1CYP11B2TRPV4MAOBPLA2G7 | |
| SCHEMBL9244079 | 0.85 | CYP11B1 (0.51) | CYP11B1CYP11B2TRPV4MAOBPLA2G7 | |
| SCHEMBL16941068 | 0.83 | CYP11B2 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL14373911 | 0.83 | CYP11B1 (0.49) | CYP11B1CYP11B2TRPV4PLA2G7 | |
| SCHEMBL13481174 | 0.82 | CYP11B1 (0.51) | CYP11B1CYP11B2TRPV4MAOBPLA2G7 | |
| SCHEMBL15142447 | 0.82 | CYP11B1 (0.48) | CYP11B1CYP11B2TRPV4PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| EP-1767526-B1 | ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1867332-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | PIK3C3, ARSA, ACR | CYP11B1 1521/4885CYP11B2 1302/4885TRPV4 4684/4885 |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | CYP11B1 265/4885CYP11B2 172/4885TRPV4 3876/4885 |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | NAT1, ERG28, SLC7A1 | CYP11B1 223/4885CYP11B2 261/4885TRPV4 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.